Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Giuffrida

Physical Medicine & Rehabilitation Fort Lauderdale, FL Medical Doctor

NPI 1740624451 CMS profile 3622906

3000 Bayview Dr Ste 100, Fort Lauderdale, FL 33306

Open in the dashboard

General payments

$270,873

619 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$428,563

6 holdings reported · through program year 2025

Research they led as principal investigator

$79,950 paid to institutions, not to them · program year 2025

Through program year 2025, Anthony Giuffrida of Fort Lauderdale, FL is reported in the CMS Open Payments database as having received $270,873 across 619 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $79,950 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $428,563 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,224 42
2024 General $48,757 72
2023 General $37,881 130
2022 General $92,010 143
2021 General $26,762 92
2020 General $21,253 42
2019 General $35,987 98
2025 Ownership $91,984 1
2024 Ownership $91,984 1
2023 Ownership $79,028 1
2022 Ownership $79,028 1
2021 Ownership $61,538 1
2020 Ownership $25,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Giuffrida
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Anthony Giuffrida were reported at $8,224. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Anthony Giuffrida Physical Medicine & Rehabilitation median Middle half National median
2019 $35,987 $133 $45–$390 $163
2020 $21,253 $88 $29–$272 $114
2021 $26,762 $116 $33–$360 $132
2022 $92,010 $123 $40–$378 $149
2023 $37,881 $131 $43–$396 $160
2024 $48,757 $141 $45–$409 $164
2025 $8,224 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Relievant Medsystems, Inc. $110,452 184 payments
  2. MML US, Inc. $110,129 166 payments
  3. Nevro Corp. $17,645 48 payments
  4. Boston Scientific Corporation $9,239 39 payments
  5. Spinal Simplicity, LLC $8,005 19 payments
  6. Medtronic USA, Inc. $2,689 36 payments
  7. Interventional Pain Technologies Inc. $2,563 4 payments
  8. Lenoss Medical LLC $2,213 3 payments
  9. Stryker Corporation $1,458 13 payments
  10. Abbott Laboratories $1,115 20 payments
  11. Other $5,366 87 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $150,898 74 payments
  2. Consulting Fee $50,613 30 payments
  3. Travel and Lodging $37,863 95 payments
  4. Food and Beverage $27,900 418 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $3,000 1 payment
  6. Education $600 1 payment
Products named General payments · program years 2019–2025
  1. ReActiv8 $110,129 166 payments
  2. Intracept Pain $52,679 71 payments
  3. Intracept Pain $47,489 91 payments
  4. Intracept Pain $27,326 39 payments
  5. Intracept Pain $17,231 35 payments
  6. Intracept Pain $17,231 35 payments
  7. Intracept Pain $13,215 39 payments
  8. Intracept Pain $13,215 39 payments
  9. Intracept Pain $13,215 39 payments
  10. Senza $8,513 15 payments
  11. Other $34,729 268 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

698

Median for Pain Management: 951

Drug cost

$3,585

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 106 $1,374
Meloxicam Generic 309 $1,013
Methocarbamol Generic 178 $892
Tizanidine Hcl Generic 22 $123
Methylprednisolone Generic 23 $107
Tramadol Hcl Generic 30 $39
Diazepam Generic 30 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$543,377

Of which drugs: $24,230

Medicare patients

462

Average age 75

Services billed

28,951

219 women, 243 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 41%
Diabetes 25%
Chronic kidney disease 24%
Depression 23%
Osteoporosis 22%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 200 2,544 $1,930
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 260 14,397 $1,277

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
$383 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

619 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record